Login to Your Account



Monogram Signs Deal With Pfizer, Out-Licenses Assay

By Karen Pihl-Carey


Tuesday, May 9, 2006
In addition to making a $25 million investment in Monogram Biosciences Inc., Pfizer Inc. agreed to globally license Monogram's HIV Co-Receptor Tropism Assay to aid in the clinical development of its CCR5 antagonist maraviroc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription